11C-CFT-PET in Presymptomatic FTDP-17: A Potential Biomarker Predicting Onset

J Alzheimers Dis. 2018;61(2):613-618. doi: 10.3233/JAD-170561.


Frontotemporal dementia with parkinsonism-linked to chromosome 17 (FTDP-17) is a rare autosomal dominant neurodegenerative disorder. Most patients with FTDP-17 carry the mutation in the microtubule-associated protein tau (MAPT) gene. Striatum is predominantly and early affected in FTDP-17. Five family members (two symptomatic patients and three presymptomatic mutation carriers) from a Chinese pedigree of FTDP-17 with N279K mutation in MAPT were enrolled. Parkinsonism was the initial symptom for symptomatic patients. 2b-carbomethoxy-3b-(4-trimethylstannylphenyl) tropane (11C-CFT) uptake was obviously affected in the putamen of two presymptomatic mutation carriers. Presymptomatic case 3, whose 11C-CFT uptake in the right putamen was normal at baseline, was still free of parkinsonism during follow-up. In conclusion, 11C-CFT-positron emission tomography could be a potential biomarker for the presymptomatic stage of FTDP-17 to predict the disease onset.

Keywords: 11C-CFT-PET; frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17); microtubule-associated protein tau (MAPT); presymptomatic mutation carriers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers / analysis
  • Brain / diagnostic imaging
  • Brain / pathology*
  • Carbon Radioisotopes
  • Female
  • Frontotemporal Dementia / diagnostic imaging*
  • Frontotemporal Dementia / genetics
  • Frontotemporal Dementia / pathology
  • Heterozygote
  • Humans
  • Male
  • Middle Aged
  • Mutation
  • Parkinsonian Disorders / diagnostic imaging*
  • Parkinsonian Disorders / pathology
  • Pedigree
  • Positron-Emission Tomography*
  • tau Proteins / genetics*


  • Biomarkers
  • Carbon Radioisotopes
  • Carbon-11
  • MAPT protein, human
  • tau Proteins